The shareholders of Nicholas Piramal India Ltd. (NPIL) have duly approved the Scheme of Amalgamation of Global Bulk Drugs and Fine Chemicals Pvt. Ltd. (GBDFC) and the Company (NPIL) at the court convened meeting held.
With the amalgamation of GBDFC, NPIL will take advantage of the opportunities that will emerge in the bulk actives and intermediates market for contract manufacturing at attractive price points of both on patent and off patent drugs for the regulated markets of Europe, US and Japan.
"Our capabilities will be critical in this business, manufacturing, process development (integrating with R&D), IPR protection, and supply chain management. NPIL will also create further market opportunity by partnering with companies across the entire product life-cycle, including the development stage. The company can manufacture and partner at each stage of the product life-cycle. Very importantly, NPIL's tract record and credibility in respecting IPR is extremely good and is respected globally," said Ajay Piramal, NPIL's Chairman.
GBDFC is one of the very few US FDA approved plants in India. The plant is unique in that it has US FDA approval for the entire facility and not merely a product line, without and deficiency or non-conformity i.e. without any 483s. It is also accredited and approved by MCA of UK, TGA of Australia and the European and Canadian Drug Authorities.